The focus of this GEN Market & Tech Analysis report is to present some of our recent industry tracking of the epigenetics signatures space as a follow-on to the GEN Report on microRNA associations and signatures that we've recently published.

In this report, we do the following:

Frame our epigenetics publications analysis
Present a comparison with our published microRNA and long noncoding publication analyses
Present epigenetics segments that are "accelerating vs. decelerating"

These analyses present a snapshot of biological content analyzed en bloc as a way to visualize segments that are expanding/contracting and where "publications coalesce".

Both text-clustering results and segmentation results show that cancer is a major focus of epigenetics research. Few other diseases have received so much attention in the epigenetics research community. The fact that “other diseases” have received less attention may be a competitive advantage for commercial players to establish unique research and patent positions in a less crowded space. We believe that our epigenetics hotspot analysis is the first to use en bloc technology landscaping methods to understand connections between cancer, putative biomarkers, and epigenetics and can be used to identify niches of opportunity for product vendors and diagnostics/therapeutics developers.

CLICK HERE to download the PDF report.

Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at enal@selectbio.us.

Gary M. Oosta holds a Ph.D. in Biophysics from Massachusetts Institute of Technology and a B.A. in Chemistry from E. Mich. Univ. He has 25 years of industrial research experience in various technology areas including medical diagnostics, thin-layer coating, bio-effects of electromagnetic radiation, and blood coagulation. Dr. Oosta has authored 20 technical publications and is an inventor on 77 patents worldwide. In addition, he has managed research groups that were responsible for many other patented innovations. Dr. Oosta has a long-standing interest in using patents and publications as strategic technology indicators for future technology selection and new product development.

To enjoy more articles like this from GEN, click here to subscribe now!

Epigenetic Signatures Landscape

This hotspot analysis is the first to use en bloc technology landscaping methods to understand connections between cancer, putative biomarkers, and epigenetics.